Close

Cristal Therapeutics Announces Appointment of Jeroen Tonnaer as Chief Business Officer

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Cristal Therapeutics, a privately-held life sciences company developing novel nanotherapeutics against cancer and other diseases, by using its patented CriPec® platform announced today the appointment of Jeroen Tonnaer as new Chief Business Officer responsible for Cristal Therapeutics’ business development, partnering and licensing activities.

Jeroen obtained an MSc in biology, a PhD in pharmacology and is a Certified Licensing Professional (CLP™). As an employee of major pharma companies, he built a broad knowledge and expertise in drug discovery & development and research strategy. He has extensive international and cross-cultural partnering & licensing expertise.

As a neuroscientist Jeroen joined Organon in 1982. He held further positions as Head DMPK, Executive Director Toxicology, and Executive Director Global Research Alliances. Subsequently he was Head Discovery Collaborations Europe for Schering-Plough. Following Schering-Plough’s acquisition by Merck & Co. (called MSD outside the US and Canada), Jeroen joined Merck’s Worldwide Licensing organization in February 2010 to become head of the European External Scientific Affairs team. Since then this team has been the driver in the identification and execution of several multimillion-$$ licensing and partnering deals

Latest stories

Related stories

Medical Negligence in 2025: Pharma’s Role in Ensuring Patient Safety

In the ever-evolving world of healthcare, the role of...

When Pharma Meets the Underworld: How Legitimate Drug Supply Chains and Illicit Drug Markets Collide

In today's global landscape, the intersection between legitimate pharmaceutical...

Pharma’s Philanthropic Scrutiny: Navigating Charity Commission Investigations in Healthcare Giving

In the healthcare sector, the intersection of pharmaceutical companies...

Role of Combination Products is on the Rise in Biopharma

In the dynamic world of today, role of combination...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back